Strongbridge Biopharma plc
DelistedCIK 1634432fmd_1E7GH46GBCT8ZZQ6ZVDH0Z5H8RManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Jun 30, 2021, 28 periods
| Line item | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | 7 | 18 | 22 | 31 |
| Cost of revenue | – | – | – | – | 1 | – | – | – |
| Gross profit | – | – | – | – | 6 | – | – | – |
| Research and development | 3 | 6 | 20 | 20 | 17 | 25 | 31 | 26 |
| Selling, general and administrative | – | – | 23 | 15 | 36 | 63 | 49 | 41 |
| Total operating expenses | 5 | 10 | 43 | 51 | – | – | – | – |
| Operating income | (5) | (10) | (43) | (51) | (74) | (82) | (67) | (43) |
| Interest expense | – | – | – | 0 | 4 | 13 | – | 1 |
| Other non-operating income (expense) | (0) | 0 | (1) | (1) | (38) | 114 | 19 | (2) |
| Income before taxes | (5) | (10) | (44) | (51) | (112) | 32 | (48) | (45) |
| Income tax expense | (0) | (0) | (0) | (3) | 2 | 1 | 2 | (0) |
| Net income from continuing operations | (5) | (10) | (44) | (49) | (113) | 32 | (49) | (45) |
| Net income | (5) | (10) | (44) | (49) | (113) | 32 | (49) | (45) |
| Net income to common shareholders | – | (10) | (44) | (49) | (113) | 32 | (49) | (45) |